Christophe Antczak
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
Peptidase Inhibition and Analysis, Ubiquitin and proteasome pathways, Cancer-related gene regulation, Protease and Inhibitor Mechanisms, Cell Image Analysis Techniques
Most-Cited Works
- → Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes(2007)452 cited
- → TMEM 41B is a novel regulator of autophagy and lipid mobilization(2018)172 cited
- → Combining integrated genomics and functional genomics to dissect the biology of a cancer‐associated, aberrant transcription factor, the ASPSCR1–TFE3 fusion oncoprotein(2013)76 cited
- → How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice(2017)72 cited
- → Ectopeptidases in pathophysiology(2001)71 cited
- → Cell viability assessment: toward content-rich platforms(2010)70 cited
- → Synthesis of Antiproliferative Cephalotaxus Esters and Their Evaluation against Several Human Hematopoietic and Solid Tumor Cell Lines: Uncovering Differential Susceptibilities to Multidrug Resistance(2008)67 cited
- → Discovery of a ZIP7 inhibitor from a Notch pathway screen(2018)66 cited
- → A new human peptide deformylase inhibitable by actinonin(2003)61 cited
- → ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells(2016)54 cited